Subscribe To
PRDS / All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy
PRDS News
By Market Watch
July 17, 2023
Pardes Biosciences stock rallies on buyout offer from MediPacific
Pardes Biosciences Inc.'s PRDS, -0.54% stock was up 12.4% in premarket trades Monday after the clinical-stage biopharmaceutical company said it agreed more_horizontal
By Zacks Investment Research
June 5, 2023
All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy
Pardes Biosciences, Inc. (PRDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m more_horizontal
By Seeking Alpha
May 17, 2023
Pardes Biosciences Seeking Strategic Alternatives
Pardes Biosciences Seeking Strategic Alternatives. Pardes' Pipeline is depleted. more_horizontal
By GlobeNewsWire
March 21, 2022
Pardes Biosciences to Present at the International Conference On Antiviral Research 2022
CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing P more_horizontal
By Benzinga
February 14, 2022
Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal
By Benzinga
February 14, 2022
Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal
By Benzinga
February 14, 2022
Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal
By Benzinga
February 3, 2022
Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19
The FDA has signed off Pardes Biosciences Inc's PRDS Investigational New Drug (IND) application for PBI-0451 for COVID-19. Get the Inside Access Tr more_horizontal